- Home
- RSKD vs ETNB Comparison
RSKD vs ETNB Comparison
Compare RSKD & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSKD
- ETNB
- Stock Information
- Founded
- RSKD 2012
- ETNB 2018
- Country
- RSKD Israel
- ETNB United States
- Employees
- RSKD N/A
- ETNB N/A
- Industry
- RSKD EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- RSKD Technology
- ETNB Health Care
- Exchange
- RSKD Nasdaq
- ETNB Nasdaq
- Market Cap
- RSKD 772.5M
- ETNB 867.4M
- IPO Year
- RSKD 2021
- ETNB 2019
- Fundamental
- Price
- RSKD $4.66
- ETNB $7.61
- Analyst Decision
- RSKD Hold
- ETNB Buy
- Analyst Count
- RSKD 9
- ETNB 7
- Target Price
- RSKD $5.97
- ETNB $30.33
- AVG Volume (30 Days)
- RSKD 547.4K
- ETNB 794.5K
- Earning Date
- RSKD 11-13-2024
- ETNB 11-07-2024
- Dividend Yield
- RSKD N/A
- ETNB N/A
- EPS Growth
- RSKD N/A
- ETNB N/A
- EPS
- RSKD N/A
- ETNB N/A
- Revenue
- RSKD $318,052,000.00
- ETNB N/A
- Revenue This Year
- RSKD $11.11
- ETNB N/A
- Revenue Next Year
- RSKD $4.62
- ETNB N/A
- P/E Ratio
- RSKD N/A
- ETNB N/A
- Revenue Growth
- RSKD 8.61
- ETNB N/A
- 52 Week Low
- RSKD $4.14
- ETNB $7.00
- 52 Week High
- RSKD $6.65
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- RSKD 44.13
- ETNB 39.65
- Support Level
- RSKD $4.99
- ETNB $7.44
- Resistance Level
- RSKD $5.19
- ETNB $8.09
- Average True Range (ATR)
- RSKD 0.18
- ETNB 0.48
- MACD
- RSKD -0.03
- ETNB -0.08
- Stochastic Oscillator
- RSKD 4.20
- ETNB 9.09
About RSKD Riskified Ltd.
Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer & Crypto, Tickets & Travel, Electronics, Home, Fashion & Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).